bone is not visualized. (b) The cortex has to be breached before angiographic changes are visible in osteosarcomata. (c) Hypervascularity may be found in both benign and malignant lesions.
Champions of angiography point out that: (a) Angiography will define the extent of a lesionradiologists may be regarded as cartographers for the surgeon. This knowledge is hardly likely to be of practical significance because it is well known that bone tumours are always more extensive than shown by radiography and surgical treatment is planned accordingly. (b) Angiography may help to show the best site for the surgeon to take a biopsy sample. However, the most malignant part of the tumour may be avascular, in which case angiographic appearances are not helpful. Osteosarcoma in the Dog The main clinical, radiological and pathological features of spontaneous canine osteosarcoma have been previously described and the dog is undoubtedly the best model for osteosarcoma in man (Owen 1 969a, b). The condition is found more often in the giant breeds such as Wolfhound and Great Dane, with lung metastasis being the major cause of death, as in man.
Transplanitatioti
Canine osteosarcoma transplantation has been successfully performed by injecting fetuses in itero, at the 6th or 7th week of gestation, with osteosarcoma cells (Owen 1 969a, b). Tumours usually develop within a few weeks of birth. Another successful method of transplantation is by injecting osteosarcoma cells into neonatal dogs which have been immunosuppressed with antilymphocyte serum.
Many tumours have been grown successfully in tissue culture for several passages and two cell lines have been established (Bostock & Owen 1970) . These cells produce sarcomas when injected into fetuses or immunosuppressed dogs but with little or no osteoid or new bone formation. Following intravenous injection, however, tumours appear to grow preferentially in bone in some dogs. Another interesting observation has been that, in some dogs injected intravenously with osteosarcoma cells at birth, tumours develop at about 3 weeks of age at the site of eruption of the incisor teeth. It is not known whether local trauma or blood supply or some other factor is responsible for this local development. After intra-arterial injection into the external iliac artery tumours develop in the femur and tibia and smaller bones of the injected limb. Tissue culture cells have also been successfully grown in Nude mice, producing tumours of histological appearance similar to tumour transplants in dogs (Oughton &Owen 1974).
Propliylacdtic X-irradiation of the Luntigs X-irradiation of one lung in young dogs previously injected intravenously with osteosarcoma cells led to less tumour development in the Xirradiated lung compared with the normal lung. This result, however, was not found when prophylactic X-irradiation was used in spontaneous cases. In 22 spontaneous cases the primary tumour was treated by amputation of the affected limb, or by X-irradiation to a total dose of 4000-5000 rad. One lung was X-irradiated with 600 rad on two occasions with a one-week interval using a 15 MeV Mullard linear accelerator (Owen & Bostock 1973) . This dose was chosen as one not likely to produce severe pneumonitis and is equivalent in biological terms to slightly more than 14 x 150 rad (relevant to normal connective tissue), a dose which has been used in bilateral prophylactic lung X-irradiation in children. At post-mortem examination 4-11 months later differences between X-irradiated and nonirradiated lungs in 20 dogs were nil or small, and in 2 dogs where the primary tumour had been X-irradiated but left in sitit more tumour grew in the X-irradiated lung. The reason for this highly undesirable effect has not been finally determined but studies on 51Cr-labelled osteosarcoma cells injected intravenously into experimental dogs have shown that tumour cells initially localize in the X-irradiated lung and in the normal lung in equal numbers, so that the mechanism is not due to 'trapping' of cells. The results of Newton (1975, personal communication) on bilateral prophylactic lung X-irradiation for osteosarcoma in man have also shown that over a five-year period there is no therapeutic benefit. Chemothercpy Treatment of primary tumours using ethoglucid administered intravenously, intra-arterially or by limb perfusion has produced only temporary regression. In vitro studies on osteosarcoma cells treated with many different drugs or hormones have shown that most cytopathic effects were produced by actinomycin D, ethoglucid, vincristine, vinblastine and mycophenolic acid. If the vinca alkaloids are classified together, the four drugs all act by different mechanisms. No results of trials are yet available on chemo-therapy following amputation in dogs clinically and radiographically free of metastases. Clinical trials in this field, which are badly needed, are limited not only by the number of research workers interested in the problem, but also by the relatively small number of dogs available for study.
Effect ofBCG Vaccine
Following amputation for osteosarcoma with or without unilateral lung X-irradiation, mean survival times have been approximately 14 weeks; Brodey (1965) has published similar figures for amputation with no other therapy. Survival for over a year has been a rarity.
A trial of intravenous injections with BCG in dogs with osteosarcoma is now in progress (Owen & Bostock 1974) . Following diagnosis the affected limb is amputated and I ampoule of BCG (Glaxo, percutaneous) containing 50-250 x 106 living organisms injected intravenously. In some instances the vaccine has been mixed with heavily X-irradiated autologous osteosarcoma cells. Repeated intravenous injections with BCG alone are made at 1, 2, 4, 8, 8, and 8 weeks. Survival times have varied from 14 to 76 weeks, with 8 of 16 dogs which can so far be assessed surviving for more than a year. The majority of dogs have eventually developed metastases in the lungs. Toxic effects have usually not been serious and have included pyrexia, anorexia and in individual dogs glossitis and pharyngitis. Anaphylactic shock can be prevented by the prior administration of antihistamine drugs. The widespread granulomas which develop particularly in the lungs and liver appear to heal if sufficient time (probably at least three months) has elapsed from the last injection. The mechanism of death of tumour or inhibition of growth of micrometastases is not fully understood but it appears likely that the nonspecific destruction of tumour cells by macrophages activated by BCG plays a major role. It is planned to alternate this type of treatment with intermittent chemotherapy. 
Surgical Treatment of Osteogenic Sarcoma
In this country the term osteogenic sarcoma is regarded as synonomous with osteosarcoma, but elsewhere it is sometimes used to embrace the three main primary tumours of bone, osteosarcoma, chondrosarcoma and fibrosarcoma (McKenna et al. 1966) . For this reason I believe that this confusing term should now be abandoned and replaced by osteosarcoma, which is not only now widely accepted, but more specific.
Compared with apparent advances in medical treatment, there is comparatively little that is new in the surgical management of osteosarcoma. Amputation, regrettably, still remains essential. I use the word 'essential' advisedly, not because I do not know that about 10% of patients with osteosarcoma can be cured by irradiation alone (Swee'.iam et al. 1971) , but because we all know that amputation is essential if our survival figure is to move into the 20% range without adjuvant chemotherapy. Hence the wisdom of Cade (1947) and his excellent, never bettered, pre-chemotherapy regime which spared so many children from unnecessary mutilation by amputation shortly before death. He insisted, however, upon amputation if survival seemed likely. There was no advantage in terms of survival in his method compared with immediate amputation but, more important, there was no disadvantage and many limbs were thereby spared.
The position has now, I consider, changed. Amputation is no less obligatory, but now most of us would agree that it is essential, not only in those likely to survive, as judged at about seven months, when some 700% of those doomed to die already show evidence of lung metastases, but in all patients and as soon as possible. Because prophylactic adjuvant chemotherapy can only act effectively against minimal disease, bulk disease, such as is bound to exist for some time during irradiation, prevents its effective action against the real target, the occult micrometastases or, to use more modern jargon, nanometastases, or perhaps, even more realistic, picometastases. Apart from the apparently reduced effect of chemotherapy upon bulk disease, I must emphasize another important reason against delay in amputation. We know that, before chemotherapy was used, two-thirds of those fated to die of their disease already showed evidence of lung metastases some seven months after starting treatment. Later, the curve begins to flatten (Fig 1) . There is no longer this convenient end-point, for we already know that metastases appear much later
